進行性胃食道がん(SAGE)におけるsFOLFOXIRI
進行性胃食道がん(SAGE)におけるsFOLFOXIRIの第II相試験
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The overall purpose of this protocol is to serve as a Single Arm Phase II trial of a four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor two (HER2) negative gastric and esophageal cancers (GEC). This study evaluates the hypothesis that the use of sFOLFOXIRI in gastroesophageal cancer (GEC) will increase response rates beyond that expected with FOLFOX, while maintaining acceptable tolerability. The primary endpoint of this study is the objective response rate (ORR) while the key secondary endpoints include the progression free survival (PFS), overall survival (OS), and adverse event (AE) rates. The goal of this study is to establish the activity level of sFOLFOXIRI, with the thought that this could be further developed in the metastatic and/or peri-operative space if a sufficiently interesting degree of efficacy is observed.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Patrick Boland, MD
- 電話番号:(732)235-2465
- メール:pb564@cinj.rutgers.edu
研究場所
-
-
New Jersey
-
Hamilton、New Jersey、アメリカ、08690
- 募集
- RWJBarnabas Health - Robert Wood Johnson University Hospital
-
コンタクト:
- Patrick Boland, MD
-
Lakewood、New Jersey、アメリカ、08701
- 募集
- RWJBarnabas Health - Monmouth Medical Center Southern Campus
-
コンタクト:
- Patrick Boland, MD
-
Long Branch、New Jersey、アメリカ、07740
- 募集
- RWJBarnabas Health - Monmouth Medical Center
-
コンタクト:
- Patrick Boland, MD
-
New Brunswick、New Jersey、アメリカ、08903
- 募集
- Rutgers Cancer Institute of New Jersey
-
コンタクト:
- Patrick Boland, MD
-
New Brunswick、New Jersey、アメリカ、08903
- 募集
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset
-
コンタクト:
- Patrick Boland, MD
-
Newark、New Jersey、アメリカ、07112
- 募集
- RWJBarnabas Health - Newark Beth Israel Medical Center
-
コンタクト:
- Patrick Boland, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Histologically and/or cytologically confirmed metastatic or unresectable adenocarcinoma of esophageal, gastroesophageal junction or gastric origin
-
Tumor is HER2 negative by standard local testing methodology
-
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 - 2
-
Measurable disease by response evaluation criteria in solid tumors (RECIST) v1.1
-
No prior systemic therapy for the present cancer given in the metastatic setting and > 6 months from administration of peri-operative chemotherapy, if applicable
o Note: up to two prior cycles of mFOLFOX6 for the present illness is permitted if patients otherwise qualify for the study with adequate baseline imaging
-
At least 18 years of age
-
Adequate bone marrow and organ functions as defined by:
-
Absolute neutrophil count ≥ 1500 cells/ μL
-
Hemoglobin ≥ 8 g/ dL
-
Platelets > 100,000 / μL
-
Creatinine ≤ 1.5 x upper limit of normal (ULN) OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault
-
Total bilirubin ≤ ULN
-
Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) < 2.5 x ULN, unless with liver metastases and then must be <5 x ULN of normal
-
Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately.
-
Ability to understand the nature of this study protocol and give written informed consent.
-
Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures.
Exclusion Criteria:
- Receipt of any investigational agents at the time of registration
- Known, untreated brain metastases
- Grade two or greater peripheral neuropathy
- Presence of any additional active malignancy within the past three years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
- For those patients who are going to receive nivolumab
- No active use of systemic corticosteroids at the time of enrollment, at a dose equivalent of 10 mg/day or prednisone
- Clinically significant autoimmune disease which is active or has required systemic immunosuppression within the last two years
- Prior organ transplant or bone marrow transplant
- History of interstitial lung disease or pneumonitis
- Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure, unstable angina or active arrhythmia
- Major surgery within the four weeks prior to initiation of study treatment
- A history of allergy or hypersensitivity to any of the study drugs
- Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
他の:4week alternating FOLFOX and a combination chemotherapy regime FOLFIRI (sFOLFOXIRI),
A cycle will constitute 28 days of treatment, which will consist of one chemotherapy combination, either FOLFOX or FOLFIRI as below:
|
This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC). The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
有害事象発生率
時間枠:3年
|
3年
|
|
|
Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors ( RECIST) criteria version 1.1
時間枠:Three Years
|
To determine the clinical efficacy of treatment regimen in terms of objective response rate. |
Three Years
|
|
Progression Free Survival (PFS)
時間枠:Three Years
|
To determine the clinical efficacy of the study treatment in terms of progressive free survival. |
Three Years
|
|
Overall Survival (OS)
時間枠:Three Years
|
To determine the clinical efficacy of the study treatment in terms of overall survival. |
Three Years
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Patrick Boland, MD、Rutgers Cancer Institute of New Jersey
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- 072204
- Pro2022000268 (その他の識別子:Rutgers Cancer Institute of New Jersey)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。